Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging psilocybin trial in treatment-resistant depression
NL-OMON55858Phase 2Active, not recruiting
- Sponsor
- COMPASS Pathways
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of psilocybin in treatment-resistant depression (TRD) and major depressive disorder (MDD) (3 arms), sponsored by COMPASS Pathways. Primary endpoint: MADRS change over time. Started Apr 2019; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON55858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55858.